Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Taskus Inc (TASK) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Taskus Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $303 (market cap $39.89B), while Taskus Inc trades at $5.46 (market cap $495.44M). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 80.5× Taskus Inc's market cap. Which is the better fit depends on your goals.
| ALNY | TASK | |
|---|---|---|
Market Cap | $39.89B | $495.44M |
Sector | Health | Technology |
52-Week High | $491.22 | $18.21 |
52-Week Low | $278.09 | $4.57 |
Enterprise Value | $38.15B | $891.14M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
TaskUs (TASK) trades at $5.41, up 2.66% today, with a neutral technical signal and bearish moving averages. The company shows strong fundamentals with a P/E of 4.79 and net income margin of 8.7%, while recent Q1 2026 earnings missed expectations. Revenue grew to $1.18 billion in 2025, and the company appointed a new CFO in June 2026.
The stock appears undervalued with a consensus price target of $9.50, offering significant upside potential. However, risks include recent earnings miss, competitive pressures in digital services, and potential market volatility. Analyst sentiment is mixed with 55% buy ratings but cautious technical indicators.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Taskus Inc
TaskUs Inc is a provider of outsourced digital services and next-generation customer experience to innovative and disruptive technology companies. It serves clients in the fastest-growing sectors, including social media, e-commerce, gaming, streaming media, food delivery and ridesharing, HiTech, FinTech and HealthTech.
Read more on TASK →
